ANIK
NASDAQ
US
Anika Therapeutics Inc. - Common Stock
$14.80
▼ $-0.18
(-1.20%)
Vol 99K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$138.6M
ROE
-38.5%
Margin
-29.3%
D/E
0.00
Beta
0.44
52W
$8–$18
Wall Street Consensus
8 analysts · Apr 20263
Strong Buy
4
Buy
1
Hold
0
Sell
0
Strong Sell
87.5%
Buy Rating
Price Chart
Similar Stocks
ARCT
Arcturus Therapeutics Holdings Inc
$174.2M
FENC
Fennec Pharmaceuticals Inc
$262.9M
KRRO
Korro Bio Inc
$75.4M
NVCT
Nuvectis Pharma Inc
$193.4M
SABS
SAB Biotherapeutics Inc
P/E 9.5
$178.0M
ELTX
Elicio Therapeutics Inc
$139.2M
ZNTL
Zentalis Pharmaceuticals Inc
$97.5M
MGNX
MacroGenics Inc
$101.8M
CRBU
Caribou Biosciences Inc
$148.6M
TNXP
Tonix Pharmaceuticals Holding Corp
$199.7M
Earnings
Beat rate: 50.0%
Next Report
May 07, 2026
EPS Estimate: $-0.16
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.16 | — | — |
| Dec 2025 | $-0.22 | $0.02 | +$0.24 |
| Sep 2025 | $-0.28 | $-0.16 | +$0.12 |
| Jun 2025 | $-0.26 | $-0.28 | $-0.02 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | -$1.3M | $26.2M | $28.2M | $27.8M | $30.6M |
| Net Income | — | -$21.9M | -$4.9M | -$4.0M | -$2.3M | $292K |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -38.5% | -38.5% | -38.5% | -38.5% | -38.5% | -38.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -14.1% | -49.0% | -49.0% | -49.0% | -49.0% | -29.3% |
| Gross Margin | 50.9% | 56.8% | 56.8% | 56.8% | 56.8% | 54.7% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 6.18 | 6.18 | 6.18 | 6.18 | 6.18 | 6.18 |
Key Ratios
ROA (TTM)
-29.8%
P/S (TTM)
1.23
P/B
1.6
EPS (TTM)
$-2.28
CF/Share
$-0.69
Rev Growth 3Y
-6.7%
52W High
$18.37
52W Low
$7.87
$7.87
52-Week Range
$18.37
Financial Health
Free Cash Flow
$4.0M
Net Debt
-$31.2M
Cash
$57.5M
Total Debt
$26.2M
As of Dec 31, 2025
How does ANIK compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
ANIK valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
1.2
▼
90%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
1.6
▼
36%
below
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
ANIK profitability vs Biotechnology peers
ROE
-38.5%
▲
43%
above
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
-29.3%
▲
90%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
54.7%
▼
30%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-29.9%
▲
36%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
ANIK financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
6.2
▲
39%
above
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
0.4
▼
55%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
ANIK fundamentals radar
ANIK
Peer median
Industry
ANIK profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ANIK vs peers: key metrics
Latest News
No related news yet